静脉胺与抑郁症的胺相比:一个系统的审查和元分析
Ahmed Elmosalamy1, Idil Tarikogullari1, Liliana Patarroyo-Rodriguez1
1Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA.
Therapeutic advances in psychopharmacology
|November 17, 2025
概括
静脉注射的胺和鼻内注射的胺在治疗耐药抑郁症方面表现出类似的有效性. 虽然IV胺可以提供更快的开始,但需要更多的头对头试验.
科学领域:
- 精神病学和药理学 精神病学和药理学
- 神经科学是一个神经科学.
- 基于证据的医学基于证据的医学.
背景情况:
- 耐治疗抑郁症 (TRD) 影响全球相当一部分成年人.
- 静脉注射 (IV) 胺和胺 (IV或鼻内注射) 是TRD的新兴治疗方法.
- 目前,只有鼻腔内注射的埃斯基坦胺被FDA批准用于TRD.
研究的目的:
- 为了比较IV胺与胺 (IV或鼻内) 在成年人与TRD的急性有效性.
- 评估作为主要结果的响应和缓解率.
- 评估作用开始的潜在差异.
主要方法:
- 一个Mantle-Haenszel随机效应元分析对头对头研究进行.
- 搜索包括主要的数据库 (MEDLINE,Embase,Cochrane,Psycinfo,Scopus) 到2025年3月.
- 分析了七项观察性研究和一项RCT,重点关注反应和缓解率.
主要成果:
- 七项研究 (n=915) 的综合分析显示,IV胺和IN胺之间的反应 (OR=1.26) 或缓解 (OR=1.31) 没有显著差异.
- 异质性是可以忽略不计的 (I2=0%),敏感性分析证实了强度.
- 证据表明,在一些研究中,IV胺的作用开始可能更快.
结论:
- 目前的观察证据表明,在TRD中,IV胺和IN胺的急性有效性相似.
- 静脉胺可以更快地开始使用,但这需要进一步调查.
- 大规模的头对头随机对照试验是必要的,以证实这些发现.
相关概念视频
01:30Electroconvulsive Therapy
835
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
835
01:24Parenteral Anesthetics: Overview
565
Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
565
01:23Antidepressant Drugs: MAOIs and Other Agents
784
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
784